Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
31 USD | +2.01% |
|
-11.48% | +12.48% |
Business Summary
Number of employees: 1,022
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Small Molecule and Gene Therapeutics
100.0
%
| 699 | 100.0 % | 938 | 100.0 % | +34.20% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
56.7
%
| 499 | 71.3 % | 532 | 56.7 % | +6.64% |
Non-United States
43.3
%
| 200 | 28.7 % | 406 | 43.3 % | +102.84% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Matthew Klein
CEO | Chief Executive Officer | 52 | 19-09-30 |
Pierre Gravier
DFI | Director of Finance/CFO | 39 | 23-07-12 |
Ellen Welch
CTO | Chief Tech/Sci/R&D Officer | - | - |
Neil Almstead
CTO | Chief Tech/Sci/R&D Officer | 57 | 99-12-31 |
Kylie O'Keefe
IRC | Investor Relations Contact | - | 18-04-30 |
Human Resources Officer | - | 17-12-31 | |
Marla Weetall
PRN | Corporate Officer/Principal | - | 02-09-30 |
Corporate Officer/Principal | - | - | |
Christine Utter
AUD | Comptroller/Controller/Auditor | 46 | 09-12-31 |
Murad Husain
PRN | Corporate Officer/Principal | - | 14-01-28 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Glenn Steele
BRD | Director/Board Member | 79 | 15-06-14 |
Chairman | 72 | 01-07-31 | |
David Southwell
BRD | Director/Board Member | 63 | 05-11-30 |
Allan Jacobson
FOU | Founder | 78 | 98-03-30 |
Emma Reeve
BRD | Director/Board Member | 63 | 18-12-17 |
Jerome Zeldis
BRD | Director/Board Member | 74 | 12-09-27 |
Alethia Young
BRD | Director/Board Member | 45 | 22-06-08 |
Matthew Klein
CEO | Chief Executive Officer | 52 | 19-09-30 |
Mary Smith
BRD | Director/Board Member | 61 | 21-06-07 |
Stephanie Okey
BRD | Director/Board Member | 64 | 18-12-17 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 76,696,785 | 74,841,517 ( 97.58 %) | 0 | 97.58 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
CLEARPOINT NEURO, INC. 3.26% | 894,578 | 3.26% | 4,857,559 $ |
Company contact information
PTC Therapeutics, Inc.
500 Warren Corporate Center Drive
07059, Warren
+908 222 7000
http://www.ptcbio.com![address PTC Therapeutics, Inc.(PTCT)](https://cdn.zonebourse.com/static/address/13450034.png)
Group companies
Name | Category and Sector |
---|---|
PTC Therapeutics International Ltd.
|
Sector
Sales per region
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.48% | 2.38B | |
+15.58% | 121B | |
+16.60% | 110B | |
+17.73% | 25.93B | |
-24.33% | 19.27B | |
-19.35% | 16.01B | |
-17.95% | 15.66B | |
-48.32% | 14.89B | |
+58.78% | 14.47B | |
+4.91% | 13.91B |
- Stock Market
- Equities
- PTCT Stock
- Company PTC Therapeutics, Inc.